Spectrum Pharmaceuticals Inc SPPI
We take great care to ensure that the data presented and summarized in this overview for SPECTRUM PHARMACEUTICALS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SPPI
View allLatest Institutional Activity in SPPI
Top Purchases
Top Sells
About SPPI
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Boston, Massachusetts.
Insider Transactions at SPPI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 31
2023
|
Keith M Mc Gahan Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
618,312
-100.0%
|
-
|
|
Jul 31
2023
|
Brittany Bradrick Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
27,380
-100.0%
|
-
|
|
Jul 31
2023
|
Juhyun Lim Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
29,759
-100.0%
|
-
|
|
Jul 31
2023
|
Seth H. Z. Fischer Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
54,066
-100.0%
|
-
|
|
Jul 31
2023
|
Nora Brennan Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
567,828
-100.0%
|
-
|
|
Jul 31
2023
|
William Ashton Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
67,660
-100.0%
|
-
|
|
Jul 31
2023
|
Jeff L Vacirca Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
295,244
-100.0%
|
-
|
|
Jul 31
2023
|
Thomas J Riga Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,839,639
-100.0%
|
-
|
|
May 26
2023
|
Nora Brennan Officer |
SELL
Open market or private sale
|
Direct |
32,387
-5.4%
|
$32,387
$1.1 P/Share
|
|
Mar 15
2023
|
Thomas J Riga Director |
SELL
Open market or private sale
|
Direct |
31,381
-6.23%
|
$0
$0.8 P/Share
|
|
Mar 15
2023
|
Keith M Mc Gahan Officer |
SELL
Open market or private sale
|
Direct |
27,197
-12.56%
|
$0
$0.8 P/Share
|
|
Mar 14
2023
|
Thomas J Riga Director |
SELL
Open market or private sale
|
Direct |
18,153
-3.48%
|
$0
$0.82 P/Share
|
|
Mar 14
2023
|
Keith M Mc Gahan Officer |
SELL
Open market or private sale
|
Direct |
15,733
-6.77%
|
$0
$0.82 P/Share
|
|
Feb 23
2023
|
Keith M Mc Gahan Officer |
SELL
Open market or private sale
|
Direct |
18,385
-2.89%
|
$0
$0.77 P/Share
|
|
Feb 22
2023
|
Keith M Mc Gahan Officer |
SELL
Open market or private sale
|
Direct |
11,990
-1.85%
|
$0
$0.76 P/Share
|
|
Feb 22
2023
|
Thomas J Riga Director |
SELL
Open market or private sale
|
Direct |
37,009
-0.99%
|
$0
$0.77 P/Share
|
|
Jan 31
2023
|
Keith M Mc Gahan Officer |
SELL
Open market or private sale
|
Direct |
41,014
-5.97%
|
$0
$0.62 P/Share
|
|
Jan 31
2023
|
Thomas J Riga Director |
SELL
Open market or private sale
|
Direct |
107,424
-5.35%
|
$0
$0.66 P/Share
|
|
Jan 30
2023
|
Keith M Mc Gahan Officer |
SELL
Open market or private sale
|
Direct |
26,138
-3.67%
|
$0
$0.54 P/Share
|
|
Jan 30
2023
|
Thomas J Riga Director |
SELL
Open market or private sale
|
Direct |
69,389
-3.34%
|
$0
$0.54 P/Share
|